The Novel DNA Cross-Linking Agent KL-50 is Active Against Patient-Derived Models of New and Recurrent Post-Temozolomide Mismatch Repair-Deficient Glioblastoma

Medicine, Neurology, Oncology,
glioblastoma   DNA cross-linking agent   mismatch repair deficiency   temozolomide   KL-50   patient-derived xenograft models   novel therapy  

Breakthrough Study on KL-50 in Treating Recurrent Glioblastoma Background Glioblastoma (GBM) is a highly malignant brain tumor, particularly in patients with IDH wild-type (IDHwt), who have a very poor prognosis. Although the current standard treatment includes surgical resection, radiotherapy, and Temozolomide (TMZ) chemotherapy, most patients eve...

TRIM21-Mediated Ubiquitination and Phosphorylation of ERK1/2 Promotes Cell Proliferation and Drug Resistance in Pituitary Adenomas

Medicine, Endocrinology, Neurology, Neurosurgery, Oncology,
TRIM21   ERK1/2   pituitary adenomas   cell proliferation   drug resistance   ubiquitination   phosphorylation  

Academic Background Pituitary adenomas (PAs) are common intracranial tumors with complex pathogenesis, often accompanied by abnormal hormone secretion. Although various treatments, such as dopamine agonists (DAs), are currently available, some patients exhibit drug resistance, leading to suboptimal therapeutic outcomes. Therefore, identifying new t...

The Prognostic Impact of CDKN2A/B Hemizygous Deletions in IDH-Mutant Glioma

Medicine, Neurology, Oncology,
glioma   IDH mutation   CDKN2A/B deletion   prognosis   neuro-oncology  

Background Introduction Glioma is one of the most common primary tumors of the central nervous system, and its prognosis and treatment methods vary significantly depending on molecular characteristics. In recent years, with the advancement of molecular pathology, IDH (isocitrate dehydrogenase) mutations have been identified as important molecular m...

Reappraisal of Prognostic Factors in CNS WHO Grade 3 Oligodendrogliomas IDH-Mutant and 1p/19q Co-Deleted: Lessons from the French POLA Cohort

Medicine, Neurology, Oncology,
oligodendroglioma   prognostic factors   IDH mutation   1p/19q co-deletion   French POLA cohort   pathological groups   contrast enhancement  

Reappraisal of Prognostic Factors in CNS WHO Grade 3 Oligodendrogliomas: Insights from the French POLA Cohort Academic Background Oligodendroglioma is a relatively rare primary brain tumor in the central nervous system (CNS), characterized by IDH gene mutations and 1p/19q co-deletion. According to the World Health Organization (WHO) classification ...

Clinical and Genetic Markers of Vascular Toxicity in Glioblastoma Patients: Insights from NRG Oncology RTOG-0825

Medicine, Neurology, Oncology, Life Sciences, Genetics,
Glioblastoma   Vascular Toxicity   Genetic Markers   Hypertension   Thrombosis   Clinical Prediction Model   Genome-Wide Association Study  

Clinical and Genetic Markers of Vascular Toxicity in Glioblastoma Patients: Insights from NRG Oncology RTOG-0825 Academic Background Glioblastoma (GBM) is a highly aggressive form of brain cancer, accounting for nearly 80% of malignant primary brain tumors. Despite standard treatments including surgical resection, radiotherapy, and chemotherapy, th...

Development of an Orthotopic Medulloblastoma Zebrafish Model for Rapid Drug Testing

Medicine, Pediatrics, Neurology, Oncology,
medulloblastoma   zebrafish model   drug testing   neural stem cells   tumor growth  

Academic Background Medulloblastoma (MB) is one of the most common malignant brain tumors in children. Although recent advances in molecular characterization and multimodal treatment have significantly improved patient survival rates, the prognosis of medulloblastoma remains closely related to molecular subtypes, particularly for patients with Grou...